Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy
Artículo
Open/ Download
Publication date
2018Metadata
Show full item record
Cómo citar
García-Salum, Tamara
Cómo citar
Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy
Author
Abstract
Purpose: We previously showed that autologous dendritic cells (DCs) loaded
with an allogeneic heat shock (HS)-conditioned melanoma cell-derived lysate, called
TRIMEL, induce T-cell-mediated immune responses in stage IV melanoma patients.
Importantly, a positive delayed-type hypersensitivity (DTH) reaction against TRIMEL
after vaccination, correlated with patients prolonged survival. Furthermore, we
observed that DTH reaction was associated with a differential response pattern
reflected in the presence of distinct cell subpopulations in peripheral blood. Detected
variations in patient responses encouraged molecular studies aimed to identify
gene expression profiles induced after vaccination in treated patients, allowing the
identification of new molecular predictive markers.
Methods: Gene expression patterns were analyzed by microarrays during
vaccination, and some of them confirmed by quantitative real-time reverse transcriptase
PCR (qRT-PCR) in the total leukocyte population of a representative group of responder
and non-responder patients. New candidates for biomarkers with predictive value were
identified using bioinformatics, molecular analysis, and flow cytometry.
Results: Seventeen genes overexpressed in responder patients after vaccination
respect to non-responders were identified after a mathematical analysis, from
which ten were linked to immune responses and five related to cell cycle control
and signal transduction. In immunological responder patients, increased protein levels of the chemokine receptor CXCR4 and the Fc-receptor CD32 were observed
on cell membranes of CD8+ T and B cells and the monocyte population, respectively,
confirming gene expression results.
Conclusions: Our study contributes to finding new molecular markers associated
with clinical outcome and better understanding of clinically relevant immunological
responses induced by anti-tumor DC-vaccines.
Indexation
Artículo de publicación SCOPUS
Identifier
URI: https://repositorio.uchile.cl/handle/2250/158977
DOI: 10.18632/oncotarget.24795
ISSN: 19492553
Quote Item
Oncotarget, Volumen 9, Issue 24, 2018, Pages 17014-17027.
Collections